Animal Treatment
The present invention relates to a composition for an animal within a particular weight range including at least one non-steroidal anti-inflammatory drug (NSAID) compound and at least one mussel extract characterised in that the therapeutic dose of NSAID compound in the composition is substantially less than the usual therapeutic dose.
1 . A composition for an animal within a particular weight range including at least one non-steroidal anti-inflammatory drug (NSAID) compound and at least one mussel extract
characterised in that
the therapeutic dose of NSAID compound in the composition is substantially less than the usual therapeutic dose.
2 . The composition as claimed in claim 1 , wherein the therapeutic dose of NSAID compound in the composition is approximately between 0.5-2 milligrams per kilogram of animal per day (mg/kg/day).
3 . The composition as claimed in either claim 1 or claim 2 wherein the NSAID is selected from any non-steroidal anti-inflammatory drug.
4 . The composition as claimed in claim any one of claims 1 to 3 , wherein the NSAID compound is a COX-2 selective NSAID compound.
5 . The composition as claimed in claim 4 , wherein the COX-2 selective NSAID compound is selected from: carprofen, maproxen, ibuprofen, ketoprofen, piroxicam, diclofenac, etodolac, flunixin, deracoxib, meloxicam, celecoxib, rofecoxib, or combinations thereof.
6 . A composition as claimed in claim 4 , wherein the COX-2 selective NSAID compound is carprofen.
7 . The composition as claimed in any one of claims 1 to 6 , wherein the mussel extract is obtained from edible members of the family Perna or Mytilus.
8 . The composition as claimed in any one of claims 1 to 7 , wherein the mussel extract is obtained from Perna canaliculus.
9 . The composition as claimed in any one of claims 1 to 8 , wherein the mussel extract is a powdered form of a mussel component not including the shell.
10 . The composition as claimed in any one of claims 1 to 9 , wherein the extract is a preparation of the lipid portion of the mussel.
11 . The composition as claimed in claim 10 wherein the lipid portion of the mussel is prepared by:
a) centrifugation of the lipid portion of the mussel;
b) freeze drying the portion obtained from step (a); and
c) forming a powder from the freeze dried portion.
12 . The composition as claimed in any one of claims 1 to 11 , wherein the level of mussel extract is approximately between 5-20 times the amount (w/v) of NSAID present in the formulation.
13 . The composition as claimed in any one of claims 1 to 12 wherein the amount of mussel extract is approximately 5.6 times the amount (w/v) of NSAID present in the formulation.
14 . The composition as claimed in any one of claims 1 to 13 , wherein the composition is in a form suitable for oral administration.
15 . A method of treatment or prevention of a connective tissue disease or the symptoms thereof in an animal,
characterised by the step of
administration to the animal a composition containing a therapeutically effective amount of at least one NSAID compound and at least one mussel extract,
wherein the therapeutic dose of NSAID compound is substantially less than the usual therapeutic dose.
16 . The method as claimed in claim 15 wherein the user:
1) is administered the composition for a period of approximately two weeks;
2) and then is indefinitely administered a stabilizing treatment with less or no NSAID compound than in the composition.
17 . The use of a therapeutically effective amount of at least one NSAID compound and at least one mussel extract, wherein the therapeutic dose of NSAID compound is substantially less than the usual therapeutic dose, in the manufacture of a medicament for the treatment or prevention of a connective tissue disease or the symptoms thereof.
18 . The method as claimed in any one of claims 15 to 17 with a composition as claimed in any one of claims 1 to 14 .
19 . The method as claimed in any one of claims 15 to 18 wherein the connective tissue disease to be treated or prevented is selected from osteoarthritis, joint inflammation, cartilage degradation, hip dysplasia, or combinations thereof.
20 . The method as claimed in any one of claims 15 to 19 wherein the composition is used to treat both the underlying cause and the symptoms associated with connective tissue disease.
21 . The method as claimed in any one of claims 15 to 20 wherein the animal to be treated is a companion animal.
22 . The method as claimed in any one of claims 15 to 21 wherein the animal to be treated is from the species canine, feline or equine.
23 . The method as claimed in any one of claims 15 to 22 wherein the animal to be treated is a domestic dog.
24 . The method as claimed in any one of claims 15 to 23 wherein the composition is used as an effective first line of treatment for connective tissue afflictions including joint inflammation, osteoarthritis and/or cartilage degradation.
25 . A composition substantially as herein described and illustrated by the examples excluding prior art disclosed within the specification.
26 . A method of treatment or prevention of a connective tissue disease, or the symptoms thereof in an animal, substantially as herein described and illustrated by the examples excluding the prior art disclosed within the specification.
36 . The use of at least one NSAID compound and mussel extract substantially as herein described and illustrated by the examples excluding the prior art disclosed within the specification.